Ñî¹óåú´«Ã½Ò•îl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Ñî¹óåú´«Ã½Ò•îl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Apr 14 2023

Full Issue

Different Takes: The Latest In The Battle Over Medication Abortion

Opinion writers tackle the current issues with medication abortion.

By rolling back the clock, the appeals court’s ruling increases the number of medical consultations required; bars the use of telehealth or mail-order pharmacies to fill prescriptions; and says mifepristone can be used only through seven weeks of pregnancy, rather than 10. (Sarah Green Carmichael, 4/13)

Do not be confused by headlines that a federal appeals court has allowed the abortion drug mifepristone to remain available. The U.S. Court of Appeals for the 5th Circuit’s action is a defeat for the rule of law, for scientific expertise and for reproductive health. (Ruth Marcus, 4/13)

The core of the 5th Circuit’s opinion, the part that is both legally outrageous and tactically clever, has mostly to do with the FDA’s decision in 2016 to extend approval of mifepristone from seven weeks of pregnancy to 10; and the agency’s Covid-era decision to allow the drug to be mailed to patients. (Noah Feldman, 4/14)

U.S. District Judge Matthew Kacsmaryk of Texas is a household name now. He’s the judge who ignored scientific evidence in favor of partisan politics and invalidated the Food and Drug Administration’s 23-year-old approval of mifepristone, the pill that has become the most common method of abortion in the U.S. (4/13)

A federal appeals court has ruled that mifepristone, one of two drugs used in medication abortion, can remain on the market as a court case over whether it was properly approved by the FDA continues. That isn’t as good or as straightforward as it sounds. (4/14)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, June 1
  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
More Morning Briefings
RSS Feeds
  • Ñî¹óåú´«Ã½Ò•îl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF